title: Immunization with a soluble recombinant HIV protein entrapped in biodegradable microparticles induces HIV-specific CD8+ cytotoxic T lymphocytes and CD4+ Th1 cells.
abstract: One of the major obstacles to the development of successful recombinant vaccines against human immunodeficiency virus (HIV) and other intracellular pathogens is the identification of a safe and effective vaccine delivery system for the induction of cell mediated immunity with soluble protein antigens. In this study it was demonstrated that immunization with a recombinant HIV envelop (env) protein entrapped in biodegradable poly(lactide-co-glycolide) (PLG) microparticles induced consistent HIV-specific CD4+ and CD8+ T-cell responses in mice. Major histocompatibility complex (MHC) class I-restricted cytotoxic T lymphocytes (CTL) responses were detected following a single systemic immunization with gp120 entrapped microparticles and when given by the intranasal (i.n.) route induced HIV-specific CD8+ CTL and secretory IgA. Furthermore immunization with gp120 entrapped in microparticles generated CD4+ T cells that secreted moderate to high levels of IFN-gamma. Therefore, PLG microparticles are a safe and effective means of delivering antigen to the appropriate processing site for the generation of class I-restricted CTL, and are also capable of inducing Th1 cells.
authors.affiliation: Biology Department, St. Patrick's College, Maynooth, Co. Kildare, Ireland.
authors.forename: A
authors.initials: A
authors.lastname: Moore
authors.forename: P
authors.initials: P
authors.lastname: McGuirk
authors.forename: S
authors.initials: S
authors.lastname: Adams
authors.forename: W C
authors.initials: WC
authors.lastname: Jones
authors.forename: J P
authors.initials: JP
authors.lastname: McGee
authors.forename: D T
authors.initials: DT
authors.lastname: O'Hagan
authors.forename: K H
authors.initials: KH
authors.lastname: Mills
mesh_terms: D000818:Animals; D000918:Antibody Specificity; D001672:Biocompatible Materials; D001673:Biodegradation, Environmental; D018414:CD8-Positive T-Lymphocytes / Q000276:immunology*; D002455:Cell Division / Q000276:immunology; D003602:Cytotoxicity, Immunologic; D004337:Drug Carriers; D015699:HIV Envelope Protein gp120 / Q000008:administration & dosage / Q000276:immunology*; D007114:Immunization; D019344:Lactic Acid; D051379:Mice; D008807:Mice, Inbred BALB C; D008863:Microspheres; D011100:Polyglycolic Acid; D000077182:Polylactic Acid-Polyglycolic Acid Copolymer; D011108:Polymers; D012995:Solubility; D018417:Th1 Cells / Q000276:immunology*
chemical_list: D001672:Biocompatible Materials; D004337:Drug Carriers; D015699:HIV Envelope Protein gp120; D011108:Polymers; D000077182:Polylactic Acid-Polyglycolic Acid Copolymer; D011100:Polyglycolic Acid; D019344:Lactic Acid